IL17A and psoriasis: The use of biologic has enabled the effective treatment of lesions in individuals with moderate to severe psoriasis, with several biologics receiving approval from the FDA, including IL-23 inhibitors, IL-17A inhibitors, and IL-12/23 inhibitors.